CY1111666T1 - Απο του στοματος συνθεση ανυδρης ολανζαπινης μορφης 1 - Google Patents

Απο του στοματος συνθεση ανυδρης ολανζαπινης μορφης 1

Info

Publication number
CY1111666T1
CY1111666T1 CY20111100651T CY111100651T CY1111666T1 CY 1111666 T1 CY1111666 T1 CY 1111666T1 CY 20111100651 T CY20111100651 T CY 20111100651T CY 111100651 T CY111100651 T CY 111100651T CY 1111666 T1 CY1111666 T1 CY 1111666T1
Authority
CY
Cyprus
Prior art keywords
core
olanzapine
salt
functional polymer
solid oral
Prior art date
Application number
CY20111100651T
Other languages
English (en)
Inventor
Martín Ignacio Díez
PÉREZ Carmen ÚBEDA
Alba Pablo Pablo
Original Assignee
Laboratorios Lesvi, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111666(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Lesvi, S.L. filed Critical Laboratorios Lesvi, S.L.
Publication of CY1111666T1 publication Critical patent/CY1111666T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Η εφεύρεση αφορά σε μια στερεά σύνθεση για την από του στόματος χορήγηση ολανζαπίνης που περιέχει πυρήνα άνυδρης ολανζαπίνης μορφής I ή κάποιου φαρμακευτικά αποδεκτού άλατος της και, προαιρετικά, φαρμακευτικά αποδεκτά έκδοχα, με τον εν λόγω πυρήνα να φέρει επικάλυψη λειτουργικού πολυμερούς που δρα ως παράγοντας δημιουργίας υμενίου. Η μέθοδος παρασκευής της περιλαμβάνει: i) παροχή άνυδρης ολανζαπίνης μορφής I ή άλατος της και, προαιρετικά, φαρμακευτικά αποδεκτών εκδόχων σε στερεά μορφή, ii) παροχή λειτουργικού πολυμερούς που δρα ως παράγοντας δημιουργίας υμενίου, iii) προετοιμασία διασποράς του εν λόγω λειτουργικού πολυμερούς σε υδατικό μέσο και εφαρμογή της διασποράς του βήματος iii) στη στερεά μορφή του βήματος i).
CY20111100651T 2005-12-26 2011-07-05 Απο του στοματος συνθεση ανυδρης ολανζαπινης μορφης 1 CY1111666T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200503183A ES2279715B1 (es) 2005-12-26 2005-12-26 Formulacion oral de olanzapina.
US75410405P 2005-12-27 2005-12-27
EP06841451A EP1965773B1 (en) 2005-12-26 2006-12-19 Oral formulation of anhydrous olanzapine form i

Publications (1)

Publication Number Publication Date
CY1111666T1 true CY1111666T1 (el) 2015-10-07

Family

ID=38468505

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100651T CY1111666T1 (el) 2005-12-26 2011-07-05 Απο του στοματος συνθεση ανυδρης ολανζαπινης μορφης 1

Country Status (13)

Country Link
US (1) US8962018B2 (el)
EP (1) EP1965773B1 (el)
JP (1) JP2009521518A (el)
KR (1) KR20080080230A (el)
AT (1) ATE504292T1 (el)
CY (1) CY1111666T1 (el)
DE (1) DE602006021231D1 (el)
DK (1) DK1965773T3 (el)
ES (2) ES2279715B1 (el)
PL (1) PL1965773T3 (el)
PT (1) PT1965773E (el)
SI (1) SI1965773T1 (el)
WO (1) WO2007074110A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
HUE041795T2 (hu) * 2010-08-31 2019-05-28 Toray Industries Bevonószer szilárd gyógyszerészeti készítményhez, gyógyszerészeti filmkészítmény, és bevonatos szilárd gyógyszerészeti készítmény
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104546807B (zh) * 2015-01-21 2020-09-01 齐鲁制药有限公司 奥氮平口腔速溶膜剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
CN1097619C (zh) 1994-07-12 2003-01-01 伯温德药品服务公司 隔潮膜涂层组合物及其生产方法以及涂层制品
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
AU719788B2 (en) * 1996-09-24 2000-05-18 Eli Lilly And Company Coated particle formulation
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
CH695862A5 (fr) 2001-12-24 2006-09-29 Sun Pharmaceutical Ind Ltd Forme cristalline I de la methyl-4-(4-methyl-1-piperazinyl) 10H-thieno [2,3-b] [1,5] benzodiazepine.
NZ535456A (en) * 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
AU2003299982B2 (en) 2002-12-20 2010-04-29 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
WO2005009407A2 (en) 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
DE602005027308D1 (de) * 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation

Also Published As

Publication number Publication date
PL1965773T3 (pl) 2011-11-30
DK1965773T3 (da) 2011-07-25
SI1965773T1 (sl) 2011-09-30
DE602006021231D1 (de) 2011-05-19
US20080311203A1 (en) 2008-12-18
EP1965773A1 (en) 2008-09-10
ES2359647T3 (es) 2011-05-25
JP2009521518A (ja) 2009-06-04
WO2007074110A1 (en) 2007-07-05
KR20080080230A (ko) 2008-09-02
ATE504292T1 (de) 2011-04-15
ES2279715A1 (es) 2007-08-16
ES2279715B1 (es) 2008-06-01
US8962018B2 (en) 2015-02-24
PT1965773E (pt) 2011-07-12
EP1965773B1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
CY1111666T1 (el) Απο του στοματος συνθεση ανυδρης ολανζαπινης μορφης 1
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
PE20050286A1 (es) Formulacion de multiparticulas que comprenden oxicodona
NO20075111L (no) Farmasoytisk sammensetning
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
NO20092314L (no) Benzamidderivater som EP4 receptoragonister
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
NO20051854L (no) Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse.
BRPI0810552A2 (pt) Composição de substância ativa, processos para preparar uma composição de substância ativa, e para preparar sementes contenda substância ativa, uso da composição de substância ativa, sementes, e, composição aquosa.
TW200716202A (en) Pediatric formulation of topiramate
ES2337596T3 (es) Antagonistas del receptor de glucacion, preparacion y usos terapeuticaos.
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
MX2007008141A (es) Composicion farmaceutica de sustancias labiles en medio acido.
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
RS53363B (en) ORAL PHARMACEUTICAL TABLETS FOR THE CONTROLLED MESALAZINE RELEASE AND THE PROCESS OF OBTAINING THEM
NO20083784L (no) Nytt sitratsalt av en indol derivativ og den farmasoytiske bruken derav
RU2008147216A (ru) Жидкая лекарственная композиция
HRP20100113T1 (hr) Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja
WO2006087358A3 (en) Composition for adjusting water quality for administration of water sanitizer sensitive medicaments or vaccines
CL2007003579A1 (es) Compuestos derivados de 5-alquiloxi-indolin-2-ona; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de afecciones del sistema nervioso central y periferico, del sistema cardiovascular, endocrino y hepatico, de la esfera
ATE479428T1 (de) Olanzapin enthaltende pharmazeutische zusammensetzung
DOP2006000144A (es) Formulación de liberación prolongada de principios activos de medicamentos